Document is current
Any future updates will be listed below
-
Authors
Young, David https://orcid.org/0000-0003-0102-5739
Harris, Clare https://orcid.org/0000-0002-8233-7509
Rahmany, Sohail https://orcid.org/0000-0003-0924-2690
Iria, Inês
Gonçalves, João
Addison, Janet
Harvey, Justin
Latter, Sue https://orcid.org/0000-0003-0973-0512
Cummings, Fraser https://orcid.org/0000-0002-9659-3247
-
Funding
Funding for this research was provided by:
Biogen Idec Ltd.
- License Information
-
More Information
Article History
Received: 15 December 2023
Accepted: 5 April 2024
First Online: 11 May 2024
Conflicts of interest
: DY has received personal fees from Galapagos. SR has received travel grant from Celltrion Healthcare and honoraria from Celltrion Healthcare and Galapagos. JG has acted as a speaker for Sandoz, AstraZeneca, Pfizer, Samsung Bioepis, and Libbs, and has received research funding from AstraZeneca and Pfizer. JA is an employee of and may hold stocks in Biogen. FC has served as consultant, advisory board member, or speaker for AbbVie, Amgen, Celltrion, Falk, Ferring, Gilead, Galapagos, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Sandoz, Biogen, Samsung, Tillotts and Takeda. He has received research funding from Biogen, Amgen, Hospira/Pfizer, Celltrion, Takeda, Janssen, GSK and AstraZeneca. The other authors have no conflicts of interest to declare.
